Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Broker tips: AstraZeneca, GSK, Persimmon, Crest Nicholson, Premier Foods, Rightmove, Moneysupermarket, Rolls-Royce

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector. The Swiss bank now has a 'buy' rating on GSK, switching from a previous 'sell', while AstraZeneca was downgraded to 'sell' from 'buy'.

Jefferies has upgraded Persimmon and cut its rating on Crest Nicholson following a review of UK housebuilders.

In a note published on Tuesday, the broker upped Persimmon to 'buy' from 'hold', and cut Crest Nicholson to 'hold' from 'buy'.

RBC Capital Markets initiated coverage of Premier Foods on Tuesday with an 'outperform' rating as it said the shares were materially undervalued even after recent strong performance.

The bank argued that Premier's "lowly" valuation owes more to historical dysfunctionality than the current state of affairs.

RBC said that assuming an underlying revenue growth rate of 2.5% by 2026, flat underlying trading margins from 2024-26, terminal growth rate from 2035 of 1.5% and an 8.5% cost of equity, its adjusted present value derived price target is 180p.

JPMorgan Cazenove downgraded Rightmove to 'underweight' from 'neutral' and cut its price target on the stock to 493.0p from 585.0p as it pointed to higher R&D and opex spend.

JPM said that Rightmove was likely to generate below sector average 7% growth in EBITDA between 2024 and 2026, "making it increasingly hard to justify" a valuation on 16.2x estimated 2024 EV/EBITDA, hence the downgrade.

Jefferies downgraded Moneysupermarket on Tuesday to 'hold' from 'buy' and slashed its price target to 265.0p from 305.0p.

The bank said it expects growth in insurance, which makes up about 50% of revenue, to decelerate in 4Q23 and throughout FY24 as the group laps tough comps and car insurance premium disinflation takes hold.

Analysts at Berenberg lowered aerospace and defence giant Rolls-Royce to 'sell' from 'hold' on Tuesday, citing an unfavourable risk/reward scenario, but marked up their target price on the stock from 100.0p to 240.0p.

The German bank stated that pricing, the most important factor for intrinsic valuation, will be "a challenge", given current reliability issues for key engines, which serve an airline industry that typically operates on low margins and appears to be approaching peak earnings.

Share this article

Related Sharecast Articles

Broker tips: Volution, Videndum
(Sharecast News) - Jefferies reiterated its 'buy' rating and 510.0p target price on Volution on Wednesday as it said the company's ability to drive margins higher, through both revenue mix and efficiency, is more than offsetting the challenging market backdrop to deliver ongoing earning upgrades.
Broker tips: Marlowe, Fevertree
(Sharecast News) - Analysts at Berenberg slightly lowered their target price on software and services firm Marlowe from 720.0p to 710.0p on Tuesday but said the group's divestment of certain Governance, Risk and Compliance software and service assets had left it with a "much cleaner and simpler-to-understand equity story".
Broker tips: JD Sports, NatWest
(Sharecast News) - Barclays downgraded JD Sports on Monday to 'equalweight' from 'overweight' and cut its price target for the stock to 140.0p from 165.0p after the retailer announced the acquisition of US rival Hibbett last week for $1.1bn.
Broker tips: NatWest, Pensionbee, Greggs
(Sharecast News) - Shore Capital reiterated its 'buy' rating on bank NatWest after a forecast-beating first quarter but said it sees the least amount of upside potential in the stock compared with the wider banking sector.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.